Advertisement

Mass vaccination programme aimed at eradication of measles in Sweden

  • B. Christenson

Summary

In 1982, a two-dose vaccination programme with the combined vaccine against measles, mumps and rubella (MMR) was introduced in Sweden [20]. The vaccination coverage was sufficiently high to reduce transmission of these viral infections [1, 2, 4, 5, 7]. The reported incidence of measles decreased from 76 per 10 000 individuals in 1982 to 1.2 per 100 000 in 1988[7]. Vaccination against measles had been introduced in Sweden in 1971 and was offered to children from the age of 18 months. In 1981, reports from child-health centres showed that 56% of all the pre-school children had been vaccinated against measles. In 1982, 88% of the 12-year-olds born in 1970 received the trivalent MMR vaccine. The coverage continued to increase and during 1989 an average of 95% of the children received the trivalent vaccine at both occasions. The vaccination coverage has been sufficiently high to reduce transmission of measles in Sweden. Evaluation of the immune status before and after vaccination is essential for the prevention of infections. At the same time as the vaccination schedule was introduced a vaccination study was started. Each year between 400 and 800 12-year-old school-children were tested on serum samples obtained prior to and after vaccination.

Only minor variations of the prevaccination immunity to measles were seen during the period 3–7 years after introduction of the programme. The age groups studied had partly been vaccinated against measles earlier. Between 12 and 16% lacked prevaccination or natural immunity. The seroconversion rate of children seronegative for measles was high, i.e. 100% in 1985 and later varied between 96 and 97%. During the follow-up period there was a declining incidence of measles, mumps and rubella. The relationship between the vaccination and reduction of disease and natural immunity strongly suggests that the association is causal and that this vaccination policy reduced the transmission of infection.

Keywords

Vaccination Coverage Measle Virus Measle Vaccine Vaccination Schedule Measle Vaccination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Böttiger M ,Christenson B, Taranger J and Bergman M (1985) Mass vaccination programme aimed at eradicating measles ,mumps and rubella in Sweden: Vaccination of schoolchildren. Vaccine 3: 113–116Google Scholar
  2. 2.
    Böttiger M, Christenson B, Romanus V, Taranger J and Strandell A (1987) Swedish experience of two-dose vaccination programme aiming at eliminating measles ,mumps and rubella. Br Med J 295: 1264–1267Google Scholar
  3. 3.
    Chen RT ,Markowitz LE ,Albrecht P ,Stewart JA ,Mofenson LM ,Preblud SR and Orenstein WA (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162: 1036–1042Google Scholar
  4. 4.
    Ghristenson B, Böttiger M and Heller L (1983) Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: First experience. Br Med J 287: 389–391Google Scholar
  5. 5.
    Ghristenson B and Böttiger M (1985) Vaccination against measles, mumps and rubella (MMR): A comparison between the antibody responses at the ages of 18 months and 12 years and between different methods of antibody titration. J Biol Stand 13: 167–172Google Scholar
  6. 6.
    Christenson B and Böttiger M (1990) Comparison of methods of screening for naturally acquired and vaccine-induced immunity to measles. Biologicals 18: 207–211Google Scholar
  7. 7.
    Ghristenson B and Böttiger M (1991) Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine 9: 326–329Google Scholar
  8. 8.
    Kirsten A, Weigle M, Murphy D, Brunell PA (1984) Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. J Clin Microbiol 19: 376–379Google Scholar
  9. 9.
    Krugman S (1983) Further-attenuated measles vaccine: characteristics and use. Rev Infect Dis 5: 477–481Google Scholar
  10. 10.
    Markowitz LE, Preblud SR, Orenstein WA, Rovira EZ, Adams NC, Hawkins GE, Hinman AR (1989) Patterns of transmission in measles outbreaks in the United States 1985–1986. N Engl J Med 320: 75–81Google Scholar
  11. 11.
    Markowitz LE, Preblud SR, Fine PEM, Orenstein WA (1990) Duration of live measles vaccine-induced immunity. Pediatr Infect DisJ 9: 101–110Google Scholar
  12. 12.
    Mathias RC, Meekison WG, Arcand TA, Schecter MT (1989) The role of secondary vaccine failures in measles outbreaks. Am J Public Health 79:475–478Google Scholar
  13. 13.
    Centers for Disease Control. Measles prevention: recommendation of the Immunization Practices Advisory Committee (ACIP) (1989) M M Wly R 38 [Suppl 9]: 1–18Google Scholar
  14. 14.
    Measles: Hungary (1989) M M Wkly Rep 38: 665–668Google Scholar
  15. 15.
    Committee on Infectious Diseases, American Academy of Pediatrics. Measles: reassessment of the current immunization policy (1989) Pediatrics 84: 1 110–1113Google Scholar
  16. 16.
    Mumps outbreaks on university campuses Illinois, Wisconsin, South Dakota (1987) MM Wly R 36: 496–505Google Scholar
  17. 17.
    Nokes DJ and Anderson RM (1988) Measles, mumps and rubella vaccine: what coverage to block transmission? Lancet ii: 1374Google Scholar
  18. 18.
    Panum PL (1940) Observations made during the epidemic of measles on the Faroe Islands in the year 1846. New York: American Public Health Association, p52Google Scholar
  19. 19.
    Pelner L (1941) Repeated attacks of measles. Am J Dis Child 62: 358–361Google Scholar
  20. 20.
    Rabo E and Taranger J (1984) Scandinavian model for eliminating measles, mumps and rubella. Br Med J 289: 1402–1404Google Scholar
  21. 21.
    Strannegård Ö, Grillner L and Lindberg IM (1975) Hemolysis-in-gel-test for demonstration of antibodies to rubella virus. J Clin Microbiol 6: 491–494Google Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • B. Christenson
    • 1
  1. 1.Department of Environmental Health and Infectious Diseases ControlKarolinska HospitalStockholmSweden

Personalised recommendations